oncology therapies

Unique payer-provider cancer treatment partnershipsUnique partnerships between payers and providers focus on keeping patients out of the hospital and on the road to remission.
How to approach value in oncologyAn eye-opening study by Precision for Value assesses cancer value frameworks.
Innovative strategies help fight multiple myeloma: What every exec should knowAs new scientific advancements occur at the genetic and protein levels, more strategies have been developed to identify and combat multiple myeloma.
Cancer MoonShot 2020 will arm oncologists with new tools
Cancer MoonShot 2020 will arm oncologists with new toolsThe Cancer MoonShot 2020 program brings together stakeholders from pharma, community and academic oncology, as well as government and scientific communities in an effort to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients.
New cancer care approach: Highmark’s cancer collaborativeCancer care has made great strides in the U.S., but effective care is still too expensive and inaccessible for many Americans. Now, payers and providers at Highmark, Allegheny Health Network and Johns Hopkins are launching a new model that could change cancer collaboration.
Obama’s precision medicine initiative: an updateThe precision medicine effort could dramatically change patient care, but will it be effective?
Are oncology pathways effective? AMCP presenters weigh inFaced with a proliferation of oncology treatments, payers have started using oncology pathways. But what do these programs look like, and are they really working?
Researchers discuss ‘less is more’ cancer treatment approachMost patients hear the word “carcinoma” or “cancer” and believe they may die if they do not seek treatment. But ASCO researchers say that may be a problematic mentality.
Provider burnout hinders cancer care qualityA look at how burnout affects providers, their patients, and the centers that employ them.
Patients demand access to investigational therapiesExpanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval.